Johnson, Johnson delay vaccine rollout in Europe


Johnson and Johnson said the planned rollout of its Covid-19 vaccine in Europe would be delayed when U.S. health agencies called for an end to the use of Jab in the U.S. and they have investigated several cases of blood clots.

The Centers for Disease Control and Prevention and the Food and Drug Administration said in a joint statement on Tuesday that they were reviewing six cases of “rare and severe” blood clots in people in the United States who received the J&J vaccine. These individuals were all women between the ages of 18 and 48 who developed symptoms within six to 13 days of vaccination.

J&J says it continues to work closely with experts and regulators to provide information and evaluation. “We are aware that thromboembolic events, including thrombocytopenia, have been reported with the Covid-19 vaccine. At present, there is no clear causal link between this rare case and the Johnson Covid-19 vaccine, ”it said.

Shares of the company were up 2.5 per cent on Tuesday.

J&J also said it was actively shutting it down Planned rollout In Europe, which was set to begin this week. The European Medicines Agency, which is reviewing a number of cases of blood clots in people who have been vaccinated with J&J, did not immediately respond to a request for comment. It has so far stated that there is no evidence of causation.

About 7m doses of J&J Jab have been administered in the United States. Federal vaccine distribution sites are expected to stop using Jab, and individual states are expected to follow suit. New York Health Commissioner Howard Zacker said in a statement Tuesday morning that the state would follow federal recommendations when evaluating the vaccine and that Jobs would suspend use “immediately.”

Pfizer shots will be given to anyone with existing J&J vaccine recruitment in the state’s mass-vaccination states, Zucker said.

The CDC said it would review the cases at a meeting of its advisory committee on immunization practices on Wednesday, and the FDA would also look into the significance of blood clots.

“We recommend that you stop using this vaccine without much caution until the process is complete,” the agencies said, adding that it was important for health agencies to properly understand and plan treatment for certain types of blood. Frozen

The J&J vaccine is the only shot Approved for use In the United States, two doses per dose are required with Pfizer and Modern vaccines. Its approval in February has been seen as an incentive to accelerate vaccination rollouts.

However, the vaccine has since caused some setbacks, including production problems at any of its supplier plants. Destroy a batch. The use of J&J Jab was also discontinued at several vaccination sites in several states following reports of adverse events.

The call to suspend vaccine rollouts due to the risk of blood clots simultaneously follows these issues. Oxford / AstraZeneca Job, Which the EMA has investigated. Last week, the EMA decided that a very rare case of abnormal blood clotting should be listed as a side effect of the AstraZeneca vaccine.

Both jobs are adenovirus based vaccines. Pfizer and Moderner shots use Messenger RNA technology.

Eric Kramer, an adenovirus specialist at the Montpellier Molecular Genetics Institute, said the side effects were “extremely rare” but that J&J’s cases did not appear to be “encouraging.”

Cody Messner, head of pediatric infectious disease at Tufts Children’s Hospital and a member of the FDA’s immunization advisory panel, said: “It’s not surprising that there seems to be some link between blood clots because the AstraZeneca vaccine also used adenovirus.”

Outside of the United States, South Africa has vaccinated only 300,000 health workers with the J&J vaccine since February.

Ordered 31 million J&J doses for Pretoria’s huge rollout. Local media in South Africa reported on Tuesday that health experts were considering a break in the local use of the J&J vaccine in light of US and European investigations. South Africa’s health ministry did not immediately respond to a request for comment.

The Norwegian authorities said on Thursday that they would announce their response to the J&J response to the decision to suspend the AstraZeneca vaccine.

Steiner Madsen, medical director of the Norwegian Medicines Agency, told NRK, the state broadcaster of the U.S. initiative: “

The CDC and FDA say the symptoms detected in six women – cerebral venous sinus thrombosis with low levels of blood platelets – usually require separate treatment for blood clots and anticoagulant drugs can be “dangerous.”

The White House insisted that the goal of 200m vaccine monitoring within the first 100 days of the Biden administration would not be hindered.

“This announcement will not have a significant impact on our immunization plans: the Johnson and Johnson vaccines have so far produced less than 5 percent of the weapons recorded in the United States,” said Jeff Gentes-19 Taskforce, coordinator of President Covid.

“Based on the steps taken by the President earlier this year, sufficient doses of Pfizer and Moderner have been secured for 300 meters of Americans in the United States.”

Additional reports by Donato Paolo Mancini in Rome, Richard Milney in Oslo and Joseph Cottrell in Johannesburg



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *